Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05961163 Terminated - Stroke Clinical Trials

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures: an Observational Study

CLIMATE
Start date: July 24, 2023
Phase:
Study type: Observational

The CLIMATE Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific efforts, somatosensory amplification, self-efficacy, health literacy and commitment to the GP, degree of urbanisation of the patients' administration district and characteristics of the patients' neighborhood are associated with these effects.

NCT ID: NCT05654870 Terminated - Schizophrenia Clinical Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

Start date: January 5, 2023
Phase: Phase 3
Study type: Interventional

This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

NCT ID: NCT05643170 Terminated - Schizophrenia Clinical Trials

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

PENNANT
Start date: November 8, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, 3-year, open-label, multi-center study in which patients with DSM-5 diagnosis of schizophrenia whose current medication(s) is not well tolerated and/or clinical symptoms are not well controlled will be switched to receive KarXT. The primary objectives of the study are to assess the long-term safety and tolerability of KarXT and assess effectiveness, persistence, and durability of effect of KarXT through the Investigator Assessment Questionnaire (IAQ) and Clinical Global Impression - Severity of Illness (CGI-S) scale in patients with a diagnosis of schizophrenia. The secondary objectives are to further assess the effectiveness using the Clinical Global Impression, Global Improvement (CGI-I), long-term safety and tolerability of KarXT, and evaluation of scores from multiple additional patient scales and assessments throughout the study.

NCT ID: NCT05526833 Terminated - Clinical trials for Schizophrenia and Related Disorders

An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

This is an open-label extension study to continue to evaluate the safety, tolerability and efficacy of the Repetitive Transcranial Magnetic Stimulation (rTMS) in subjects with schizophrenia or schizoaffective disorder who previously completed the treatment study of the protocol #8116 (NCT05319080). Protocol #8116 investigates the clinical efficacy of open-label individualized MRI-guided TMS applied to the left temporoparietal junction (TPJ) in schizophrenia patients. Participating patients who have completed the 4-week project #8116 can be screened for eligibility for this extension study in which they will continue treatment/assessment. They will be divided into three groups (non-responders, partial responders, or full responders) based on a reduction in the Auditory Hallucination Rating Scale (AHRS) scores from the study #8116.

NCT ID: NCT05164289 Terminated - Clinical trials for Schizophrenic Disorders

Interest of EMDR Schizophrenic Disorders

EMDRpsychose
Start date: December 10, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to determine the interest of the use of EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the management of psychotic disorders, in particular schizophrenic disorders.

NCT ID: NCT04975035 Terminated - Schizophrenia Clinical Trials

A Prospective, Open-ended, Multi-center Study of Schizophrenia Patients Switching to Zolodine

Start date: January 1, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Through self-controlled studies on metabolic syndrome related indicators, efficacy and other adverse reactions in patients with schizophrenia who developed metabolic syndrome after treatment with other antipsychotics, switched to Zoladine capsules (ziprasidone hydrochloride capsules). To evaluate the clinical application value of switching to Zolodine for schizophrenia patients with metabolic syndrome, and to explore the drug selection strategy for long-term treatment of schizophrenia patients.

NCT ID: NCT04825860 Terminated - Schizophrenia Clinical Trials

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Start date: March 29, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.

NCT ID: NCT04742413 Terminated - Schizophrenia Clinical Trials

A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

RESPECT
Start date: December 29, 2020
Phase:
Study type: Observational

A 12-Month Observational Prospective Multicentre Cohort Study based on existing and newly collected data of schizophrenia patients followed-up for one year in secondary care settings (psychiatric services). Schizophrenia patients will be enrolled in a consecutive manner over a period of 6 month into two cohorts according to their prescribing switching treatment: to lurasidone (cohort A) and to another SGA (cohort B).

NCT ID: NCT04548622 Terminated - Schizophrenia Clinical Trials

Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Results

Start date: September 2012
Phase: N/A
Study type: Interventional

The primary purpose of this study was to conduct fMRI neuroimaging studies prior to and subsequent to the rTMS intervention. The intent was to ascertain changes in regional brain activation and connectivity that most robustly predict level of improvement in auditory hallucinations elicited by bilateral rTMS as assessed by the primary outcome variables.

NCT ID: NCT04421456 Terminated - Schizophrenia Clinical Trials

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

Start date: August 18, 2020
Phase: Phase 2
Study type: Interventional

This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.